Corporate Profile Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. ZerenexTM has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage... More >> Featured Report   2012 10-K

Stock Quote KERX (Common) Exchange NASDAQ (US Dollar) Price $8.05 Change (%)   0.11 (1.39%) Volume 1,392,027 Data as of 05/21/13 4:00 p.m. ET Minimum 20 minute delay Refresh quote Receive E-mail Alerts

Recent News

Date Title   05/07/13 Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results 05/06/13 Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial Results 03/14/13 Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference 03/13/13 Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.